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Poster Session-II 137evident in lymphopenic patients, suggesting that lymphopenia-
driven proliferation and apoptosis skew Treg reconstitution. This
homeostatic process does not affect the survival of other CD4 T
cell subsets, resulting in a relative deficiency of Treg post-HSCT.
Our findings provide important information for developing strate-
gies to modulate Treg and promote immune tolerance after
HSCT.382
CELLULAR IMMUNE RECONSTITUTION AND ITS IMPACT ON CLINICAL
OUTCOME IN CHILDREN WITH THALASSEMIA MAJOR UNDERGOING A
MATCHED RELATED ALLOGENEIC BONE MARROW TRANSPLANT (BMT)
Rajasekar, R., Mathews, V., Lakshmi, K.M., George, B.,
Viswabandya, A., Chandy, M., Srivastava, A. Christian Medical College,
Vellore, Tamil Nadu, India
We have prospectively analyzed cellular immune reconstitution
(IR) in pediatric patients with ß thalassemia major who underwent
myeloablative HLA matched related allogeneic BMT at our centre.
A total of 63 such consecutive patients were included in the study.
Samples from bone marrow graft and post-transplant peripheral
blood samples from recipients (day 15, 28, 45 and 2, 3, 6, 9 and 12
months) were assessed for stem cells, lymphocytes and dendritic
cell subsets. The median age of the cohort was 7 years (range: 2–
14) and there were 37 (59%) males. All patients received myeloabla-
tive conditioning regimen. Bone marrow was the graft source in
61(unprimed in 37; G-CSF primedmarrow in 24) while two patients
received PBSC. Cyclosporine and short course methotrexate was
used as GVHD prophylaxis. A CD34 cell dose above the median
value of 7.3  106/Kg had a lower incidence of bacterial (P 5
0.003) and fungal (P5 0.003) infections in the post-transplant period
and was not associated with an increased risk of GVHD.Themedian
time to engraftment was not different between these groups (17 vs.
16 days, P 5 0.531). Among cases that did develop grade II-IV
GVHD the absolute CD8 (116 vs.52 cells/ml, P5 0.012), both naı¨ve
(74 vs. 9 cells/ml, P 5 0.005) and memory counts (44 vs.21 cells/ml,
P5 0.010) were significantly higher on day 15. Only one of eight pa-
tients who eventually developed acute GVHD had evidence of acute
GVHD at this time point. Fifteen patients (24%) rejected their graft
(7 primary and 8 secondary). The day 28 NK cell count was signifi-
cantly associated with secondary graft rejection, EFS and OS when
analyzed as continuous variable in univariate analysis (P 5 0.044,
0.013 and 0.034 respectively). On a multivariate analysis, patients
with #142 NK cells/ml (median value) on day 28 had significantly
higher rejection (HR 5 11.1, P 5 0.038) and lower EFS (HR 5
16.3, P 5 0.034). Table 1 compares the characteristics of cases
with a day 28 NK cell count # the median value and those above
it. These data suggest that the stem cell dose along with patterns
of cellular IR have a significant impact on clinical outcomes such
as infection, rejection and EFS.Table 1. Comparison of low and high day 28 NK cell count
patient groups
Day 28 NK
cell count
[n (%) / median (range)]CharacteristicsLow
(# 142/ml)
n526High
(142/ml.)
n526 P-valueAge (years) 7 (2 – 14) 8 (2 – 13) 0.904
Males 15 (58) 16 (62) 1.000
Sex mismatch transplant 10 (39) 9 (35) 1.000
Lucarelli Class III 14 (54) 11 (42) 0.579
TNC (10E8/Kg) 4.2 (1.7 – 10) 4.6 (1.7 – 22.7) 0.442
ANC .500 /mm3 17 (11 – 23) 16 (13 – 20) 0.358
Acute GVHD (Grade II-IV) 3 (12) 4 (15) 1.000
Chronic GVHD 2 (9) 3 (13) 1.000
Secondary graft rejection 7 (35) 1 (4) 0.021
EFS at 3 years 64 6 10% 96 6 4% 0.006383
RAPID GENERATION OF ANTIGEN-SPECIFIC T CELLS FOR PRE-CLINICAL
AND CLINICAL APPLICATIONS USING A NOVEL MINI CELL BIOREACTOR
Brenner, L.1, Leen, A.M.1, Wilson, J.2, Heslop, H.E.1, Dotti, G.1,
Rooney, C.M.1, Vera, J.F.1 1Baylor College of Medicine, Houston, TX;
2Wilson Wolf Manufacturing, New Brighton, MN
The production of antigen-specific T cells for the reconstitution
of tumor or pathogen-specific immunity after HSCT is limited by
the time taken to produce large T cell numbers, while retaining
function and specificity. The requirements for expansion of anti-
gen-driven cytotoxic T lymphocytes (CTLs) are rigorous, and in
some cases only possible in 2 cm2 wells. Conventional cell growth
is limited by gas exchange, nutrients and waste build-up. Bioreac-
tors developed to solve these problems tend to be complex and ex-
pensive and not always conducive to antigen-specific T cell
growth. We have now explored the use of a new static mini Cell
Bioreactor (CBR); essentially a flask with a gas permeable mem-
brane base. The O2/CO2 exchange from the base allows large
heights of media above the cells reducing nutrient limitations,
waste build-up, and manipulation. We tested two different sizes
of CBR, 10 cm2 and 100 cm2 that hold a maximum of 40mL
and 2000L of media, respectively. We were able to generate and
expand Epstein-Barr virus antigen-specific cytotoxic T lympho-
cytes (EBV-CTLs) from normal donors by coculturing antigen
presenting cells (APC) (1.4E105 x cm2) with established EBV
CTL (4.3E103 x cm2) at an optimized cell density and stimulator:
responder ratio (32:1). These culture conditions produced higher
cell yields in the CBR vs. conventional method (42.5 fold 614.8
vs 3.4 fold 61.2 within 7 days) without media change, and manip-
ulation restricted to cytokine addition every 3–4 days. A single
100cm2 bioreactor could produce up to 800E106 antigen-specific
T cells from a starting 10E106 PBMC, which would have re-
quired approximately 320 wells in 24 well plates under standard
culture conditions. The CD4:CD8 T cell ratio and phenotype
was similar to those expanded using the conventional method
(CD27 48% vs 52.4%, CD28 65.2% vs 62.2%, CD62L 53.15%
vs 54.5%, CD45RO 58.1% vs 55.7%, and CD45RA 51.1% vs
54.9%). Antigen specificity, as evaluated by tetramer analysis,
and IFN-g ELIspot and chromium release assays revealed no sig-
nificant differences. In summary, we have successfully utilized the
new mini Cell Bioreactor technology to induce optimal in vitro ex-
pansion of virus-specific CTLs with minimal handling. This new
cell culture technology can readily be extended it to others cells
products in order to facilitate the application of cell therapy ap-
proaches. This work was supported in part by a Production Assis-
tance for Cellular Therapies PACT (NO1HB37163–C001) from
NHLBI384
ABSOLUTE LYMPHOCYTE COUNT KINETICS MAY PREDICT THE CLINICAL
OUTCOME AFTER RELATED ALLOGENEIC PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION WITH A BUSULFAN-BASED REDUCED-INTEN-
SITY CONDITIONING REGIMEN
Yakushijin, K., Fukuda, T., Saito, B., Kurosawa, S., Asakura, Y.,
Azuma, T., Kim, S.-W., Mori, S.-i., Tanosaki, R., Heike, Y.,
Takaue, Y. National Cancer Center Hospital, Tokyo, Japan
In autologous hematopoietic stem cell transplantation (HSCT),
early recovery of the absolute lymphocyte count (ALC/mm3) is
known to be associated with better overall survival (OS). Although
similar observations have been reported after myeloablative alloge-
neicHSCT, little is known in the setting of RIST. Previously, we ob-
served that donor T-cell chimerism at 1 month after busulfan-based
RIST may predict the clinical outcome (Saito et al., BBMT, 2008).
To further extend this analysis, we retrospectively reviewed themed-
ical records of 88 patients (median age, 54 y (29–68)) who underwent
busulfan-based RIST at our hospital between 2000 and 2007. The
conditioning regimen consisted of busulfan (oral 8 mg/kg or iv 6.4
mg/kg) and fludarabine (180 mg/m2, n 5 41) or cladribine (0.66
mg/kg, n 5 47), and one patient received 2Gy TBI. The diagnosis
included ML (n 5 37), AML/MDS (n 5 38), and other (n 5 13).
All patients received G-CSF-mobilized PBSCs from related donors
